[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2017 Switzerland Automated Microbiology Market: Molecular Diagnostics, Identification, Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics-- Specimen, Test, and Sales Forecasts, Competitive Strategies, Opportunities

March 2017 | 500 pages | ID: 287ED4C6A7AEN
Venture Planning Group

US$ 4,365.00 US$ 4,850.00 -10 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new report from VPGMarketResearch.com examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay and application; profiles leading players and potential market entrants; and suggests alternative market penetration strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems.The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans.Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.

Market Segmentation Analysis
  • Volume and sales forecasts for over 100 infectious disease assays by individual test.
  • Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
Specimen Types
  • Urine
  • Sterile Fluids: Blood, Serum, CSF
  • Throat Swabs, Respiratory Secretions
  • Genital Secretions
  • Stool
  • Abscess/Wound
  • Sputum
  • Saliva
Applications
  • Microbial Identification
  • Antibiotic Susceptibility
  • Urine Screening
  • Blood Cultures
Review of Major Automated Systems
  • Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers.
Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Technology Review
  • Assessment of molecular diagnostic, monoclonal antibody, immunoassay,and other technologies and their potential applications for the microbiology market.
  • Global listings of companies developing or marketing microbiology products by individual test.
Competitive Assessments
  • Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategic Recommendations
  • Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.
  • Design criteria for decentralized testing products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
Contains 500 pages and 54 tables
1. INTRODUCTION

2. MARKET OVERVIEW

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

7. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

  1. INTRODUCTION
  2. CANCER DIAGNOSTIC CLASSIFICATION
  3. ACTH
  4. ALPHA FETOPROTEIN (AFP)
  5. BETA 2 MICROGLOBULIN
  6. CA 15 3/27.29
  7. CA 199
  8. CA 125
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATE    SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL CANCER DIAGNOSTICS
  27. ONCOGENES
  Abl/abl bcr
  AIB1
  BCL2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP    17
  ErbB
  HPC1
  Nmyc
  P40
  P51
  P53
  PIK3CA
  PTI1
  Ras
  Reg
  Sis
  Src
  28. POLYPEPTIDE GROWTH FACTORS
  Basic Fibroblast Growth Factor
  Beta    TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor    Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
  Alpha    Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma    Interferon
  Interleukin    1 (IL1)
  Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING CANCER DIAGNOSTICS
  NAcetylglucosamine
  Actin
  Alpha    Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD    F9
  BLCA 4
  Blood Group Antigens A, B, H
  CA
  CA 72    4/TAG    72
  CA
  CA 242
  CA 549
  CAM
  CAR    3
  Cathepsin    D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster    5/5A Antigen
  CTA
  CU18
  DR    70
  DU    AN2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1    >3)    Lfucosyltransferase
  Gastrin    Releasing Peptide (GRP)
  GDCFP    15
  Glucagon
  Glycoamines
  H23
  Her    2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21    1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA 130
  NMP22
  OA 519
  Opiod Peptides
  P    glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki 67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA 1/SLX
  SN10
  Somatostatin
  TA 90
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen

8. INSTRUMENTATION REVIEW AND MARKET NEEDS

9. CURRENT AND EMERGING TECHNOLOGIES

  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
  3. MOLECULAR DIAGNOSTICS
  4. CHROMOSOME ANALYSIS
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TW DIMENSIONAL GEL ELECTROPHORESIS (2    DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES

10. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

11. COMPETITIVE PROFILES

  Abbott
  AdnaGen/Alere
  Agilent Technologies
  Applied Gene Technologies
  Arca Biopharma
  Beckman Coulter/Danaher
  Becton Dickinson
  Biomedical Diagnostics
  bioMerieux
  Bio-Rad
  CellSearch
  Cepheid
  Correlogic Systems/Vermillion
  Decode Genetics
  Diadexus
  Diagnocure
  Diasorin
  Eiken Chemical
  Elitech Group
  Enterix
  Enzo Biochem
  Epigenomics
  Exact Sciences
  Fujirebio
  Guided Therapeutics
  Hologic/Genrobe
  Kreatech/Leica
  Kyowa Medex
  Mackay Life Sciences
  Myriad Genetics
  OncoLab
  Ortho    Clinical Diagnostics
  Panacea Pharmaceuticals
  Polartechnics
  Polymedco
  PreMD
  Qiagen
  Quest Diagnostics
  Radient Pharmaceuticals
  Roche
  Scienion
  Sequenom
  Siemens Healthcare
  Takara Bio
  Targeted Diagnostics & Therapeutics
  Tosoh
  Thermo Fisher/Affimetrix
  Veridex
  Wako Pure Chemicals
  Wallac/PE
  Zila

12. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts
Cancer Diagnostic Volume Forecast by Test
Cancer Diagnostics Sales Forecast by Test
ACTH Test Volume and Diagnostics Sales Forecast
AFP Test Volume and Diagnostics Sales Forecast
Beta    2 Microglobulin Test Volume and Diagnostics Sales Forecast
CA 15 3/27.29 Test Volume and Diagnostics Sales Forecast
CA 199 Test Volume and Diagnostics Sales Forecast
CA 125 Test Volume and Diagnostics Sales Forecast
Calcitonin Test Volume and Diagnostics Sales Forecast
Cathepsin Test Volume and Diagnostics Sales Forecast
CEA Test Volume and Diagnostics Sales Forecast
Chromogranin Test Volume and Diagnostics Sales Forecast
Colon    specific Antigen Test Volume and Diagnostics Sales Forecast
Cytokeratins Test Volume and Diagnostics Sales Forecast
Estrogen Receptor Test Volume and Diagnostics Sales Forecast
Ferritin Test Volume and Diagnostics Sales Forecast
Gastrin Test Volume and Diagnostics Sales Forecast
HCG Test Volume and Diagnostics Sales Forecast
Insulin Test Volume and Diagnostics Sales Forecast
Interferons Test Volume and Diagnostics Sales
Interleukins Test Volume and Diagnostics Sales Forecast
Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast
NSE Test Volume and Diagnostics Sales Forecast
Nucleolar Test Volume and Diagnostics Sales Forecast
Occult Blood Test Volume and Diagnostics Sales Forecast
Oncogenes Test Volume and Diagnostics Sales Forecast
Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast
PAP Smear Test Volume and Diagnostics Sales Forecast
Parathyroid Hormone Test Volume and Diagnostics Sales Forecast
Progesterone Receptor Test Volume and Diagnostics Sales Forecast
PAP Test Volume and Diagnostics Sales Forecast
PSA Test Volume and Diagnostics Sales Forecast
S    100 Protein Test Volume and Diagnostics Sales Forecast
Serotonin Test Volume and Diagnostics Sales Forecast
Sialic Acid Test Volume and Diagnostics Sales Forecast
Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast
TDT Test Volume and Diagnostics Sales Forecast
Thymidine Kinase Test Volume and Diagnostics Sales Forecast
Thyroglobulin Test Volume and Diagnostics Sales Forecast
TPA Test Volume and Diagnostics Sales Forecast
Cancer Diagnostic Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta    2 Microglobulin Tests
Major Companies Developing or Marketing CA 15 3/27.29 Tests
Major Companies Developing or Marketing CA 199 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications in Cancer Diagnosis
Oncogenes Potential Applications in Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications in Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis


More Publications